title: A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India.
abstract: In this communication, the authors discuss the issue of individualization of thyrotropin suppressive therapy in differentiated thyroid carcinoma (DTC) patients and share their views with respect to optimizing the dose of levothyroxine (LT) prescription both during discharge from radioiodine therapy ward and during follow-up. The changing management paradigm at our Institute during post-thyroidectomy period and during the preparation for radioiodine scan is also briefly highlighted. Five factors can be identified as important determinants for the dose individualization approach: (1) Persistence or absence of metastatic disease, (2) the risk characteristics of the patient and the tumor (3) patient's clinical profile, symptomatology, and contraindications (4) the feasibility to ensure a proper thyroid stimulating hormone TSH suppression level (depends on patient's socio-economic and educational background, the connectivity with the local physician and his expertise) (5) time period elapsed since initial diagnosis. While discussing each individual case scenario, the authors, based upon their experience in one of the busiest thyroid cancer referral centers in the country, discuss certain unaddressed points in the current guideline recommendations, deviations made and some challenges toward employing them into practice, which could be situation and center specific. In addition to these, the value of clinical examination, patient profile and detailed enquiry about clinical symptomatology by the attending physician in each follow-up visit cannot be overemphasized. According to the authors, this aspect, quite important for dose determination in an individual, is relatively underrepresented in the present guidelines. It would also be worthwhile to follow a conservative approach (till clear data emerges) in patients who have characteristics of "high-risk" disease, but are clinically and biochemically disease free, if no medical contraindications exist and patient tolerates the suppressive therapy well. This would be particularly applicable in the presence of aggressive histopathological variants, where, in the event of recurrence/metastasis, the disease demonstrates adverse prognosis and higher incidence of radioiodine refractoriness. At the end, certain important and noteworthy concepts pertaining to LT prescription that has definitive practical implications for the suppressive therapy in DTC patients are described.
authors.affiliation: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
authors.forename: Sandip
authors.initials: S
authors.lastname: Basu
authors.forename: Amit
authors.initials: A
authors.lastname: Abhyankar
authors.forename: Ramesh
authors.initials: R
authors.lastname: Asopa
authors.forename: Devendra
authors.initials: D
authors.lastname: Chaukar
authors.forename: Anil K
authors.initials: AK
authors.lastname: Dcruz
keywords: Differentiated thyroid carcinoma; levothyroxine; thyroid stimulating hormone TSH suppression; thyrotropin-suppressive therapy
references.citation: Ann Med. 2002;34(7-8):554-64
references.pmid: 12553495
references.citation: J Clin Endocrinol Metab. 1996 Dec;81(12):4318-23
references.pmid: 8954034
references.citation: J Clin Endocrinol Metab. 2007 Jul;92(7):2610-5
references.pmid: 17426094
references.citation: Eur J Endocrinol. 2006 Jun;154(6):787-803
references.pmid: 16728537
references.citation: Thyroid. 2012 Dec;22(12):1200-35
references.pmid: 22954017
references.citation: Thyroid. 2009 Nov;19(11):1167-214
references.pmid: 19860577
references.citation: Thyroid. 2006 Dec;16(12):1229-42
references.pmid: 17199433
references.citation: Thyroid. 1998 Sep;8(9):737-44
references.pmid: 9777742